)
Option Care Health (OPCH) investor relations material
Option Care Health Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Business overview and market positioning
Largest independent provider of home and alternate site infusion therapy in the U.S., licensed in all 50 states with over 90 pharmacies and 170 infusion centers.
Serves over 300,000 unique patients annually, offering a broad spectrum of infusion therapies for acute and chronic conditions.
National scale leveraged as a competitive advantage, but success depends on strong local execution and relationships.
Recent market exits by competitors have allowed for increased market share, especially in acute care transitions.
Expanding product portfolio, including limited distribution drugs, and deepening partnerships with pharma and referral sources.
Stelara and biosimilar transition
Stelara, a key chronic therapy, faces a $60–$70 million headwind in 2025 due to loss of historical discounts and IRA negotiations.
Transition to biosimilars and new manufacturer pricing models expected to further impact revenue and margins into 2026.
Ongoing negotiations with Janssen and other manufacturers to secure favorable terms and manage patient transitions.
Expectation that profit pool will stabilize post-2026 as market dynamics reach equilibrium.
No other drugs in the next IRA tranche are expected to have a material impact on the portfolio.
Financial outlook and growth expectations
Acute business saw mid-teens growth in 2023 due to competitor exits and strong execution; future growth expected in mid-single digits.
Chronic business to experience revenue headwinds from biosimilar transitions but expects low-double-digit growth, with gross profit margins improving ex-Stelara.
EBITDA and adjusted EPS are projected to grow in 2025 and 2026, with confidence in delivering on guidance.
Long-term outlook remains for high single-digit top-line and low double-digit bottom-line growth, with 2026 as a transition year.
23 consecutive quarters of meeting commitments, emphasizing disciplined guidance and execution.
Next Option Care Health earnings date
Next Option Care Health earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage